Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

BACKGROUND: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Rosas, Ivan O., Bräu, Norbert, Waters, Michael, Go, Ronaldo C., Malhotra, Atul, Hunter, Bradley D., Bhagani, Sanjay, Skiest, Daniel, Savic, Sinisa, Douglas, Ivor S., Garcia-Diaz, Julia, Aziz, Mariam S., Cooper, Nichola, Youngstein, Taryn, Sorbo, Lorenzo Del, Zerda, David J. De La, Ustianowski, Andrew, Gracian, Antonio Cubillo, Blyth, Kevin G., Carratalà, Jordi, François, Bruno, Benfield, Thomas, Haslem, Derrick, Bonfanti, Paolo, van der Leest, Cor H., Rohatgi, Nidhi, Wiese, Lothar, Luyt, Charles Edouard, Bauer, Rebecca N., Cai, Fang, Lee, Ivan T., Matharu, Balpreet, Metcalf, Louis, Wildum, Steffen, Graham, Emily, Tsai, Larry, Bao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022847/
https://www.ncbi.nlm.nih.gov/pubmed/35475258
http://dx.doi.org/10.1016/j.eclinm.2022.101409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022847/
https://www.ncbi.nlm.nih.gov/pubmed/35475258
http://dx.doi.org/10.1016/j.eclinm.2022.101409

Ejemplares similares